A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma
A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma
A non-profit study designed with the aim of analysing the phenotype and molecular
 characteristics (central review) and evaluating prospectively the role of PET-scans in the
 management of primary mediastinal lymphoma treated with conventional approaches.
Inclusion Criteria:

 -  Primary mediastinal diffuse large B-cell lymphoma, CD20 positive. Patients must have
 histological confirmation of the diagnosis, and in addition have a dominant mass
 within the anterior mediastinum.

 -  No prior treatment of lymphoma. Patients may have received corticosteroids for up to 1
 week for the relief of local compressive symptoms.

 -  Any stage of disease.

 -  Age at least 18 years.

 -  Fit to receive chemotherapy with curative intent.

 -  Able and willing to give informed consent, and to undergo staging including PET
 scanning

 -  Willingness to comply with an appropriate contraceptive method in women of
 childbearing potential or men.

 Exclusion Criteria:

 -  Evidence of clinically significant cardiac disease, as defined by history of
 symptomatic ventricular arrhythmias, congestive heart failure or myocardial infarction
 within 12 months before study entry. Cardiac compromise due to local extension of
 lymphoma will not be an exclusion criterion in the absence of other cardiac disease.

 -  Impairment of bone marrow function (WBC <3.0x109/L, ANC <1.5x109/L, PLT <100x109/L),
 unless due to involvement by lymphoma.

 -  Major impairment of renal function (serum creatinine >2x upper normal) or liver
 function (ASAT/ALAT >2,5 upper normal, total bilirubin >2,5x upper normal), unless due
 to lymphoma involvement.

 -  Known HIV infection. Patients will not be tested routinely.

 -  Pregnant or lactating women.

 -  Any psychological, familial, sociological or geographical condition potentially
 hampering compliance with the study protocol and follow-up schedule; those conditions
 should be discussed with the patient before registration in the trial